Deals
Fulcrum Shareholders Would Keep About 5% Of A Migraine Drug Developer, Plus A $270 Million Dividend
Fulcrum's amended merger filing with Slate Medicines shows a $270.5 million dividend and a December 3 shareholder vote.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Deals
Fulcrum's amended merger filing with Slate Medicines shows a $270.5 million dividend and a December 3 shareholder vote.
SEC Filings
The browser maker also said its desktop users hit 100 million in October, and it will report full results on November 17.
SEC Filings
The awards pay nothing below the 40th percentile of relative shareholder return and top out at 250% of target.
SEC Filings
The egg producer says the butter wind-down charges are non-cash inventory write-downs, with no future cash spending expected.
Deals
The food-processing equipment maker lifted its margin and EPS midpoints and expanded its repurchase program to $700 million.
Deals
The U.S. waiting period on the planned merger expired Monday night, but California's suspended approval still has to be reinstated.
SEC Filings
The drug developer reported $444.0 million in cash, which it says lasts into 2028, as a $40.8 million warrant gain cut its quarterly loss.
Earnings
Third-quarter net income rose from $137 million as Parkland's fuel, terminal and refinery assets joined the books; the payout rises 1.25%.
SEC Filings
Pfizer's quarterly report says the pilot, expected to start in January 2027, faces ongoing litigation; the company is still evaluating its impact.
Deals
The KFC and Pizza Hut operator's third-quarter operating profit rose 13% to $451 million, and its board added $1 billion to buybacks.
Deals
The refiner's third-quarter net income hit $570 million, and the CEO called it the best quarter in company history.
SEC Filings
The $377,162,666 preferred-stock purchase carries director nomination rights, debt consent rights and a one-year-plus standstill.